Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM5A | P29375 | 6/20 | 0.43 |
| ▸ | PHF8 | Q9UPP1 | 4/20 | 0.43 |
| ▸ | KDM4C | Q9H3R0 | 4/20 | 0.43 |
| ▸ | DNM1 | Q05193 | 3/20 | 0.42 |
| ▸ | CES2 | O00748 | 3/20 | 0.41 |
| ▸ | CES1 | P23141 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | KDM5C | P41229 | 1/20 | 0.41 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7825058 | 0.98 | KDM5A (0.42) | KDM5APHF8KDM4CDNM1CES2 | |
| SCHEMBL27418655 | 0.91 | — | — | |
| SCHEMBL28924905 | 0.88 | CA12 (0.41) | KDM5APHF8KDM4C | |
| SCHEMBL23616238 | 0.80 | — | — | |
| SCHEMBL25270374 | 0.79 | CA12 (0.50) | DNM1CES2CES1MEN1FAAH | |
| SCHEMBL25227944 | 0.79 | CA12 (0.50) | DNM1CES2CES1MEN1FAAH | |
| SCHEMBL25272251 | 0.79 | CA12 (0.50) | DNM1CES2CES1MEN1FAAH | |
| SCHEMBL25276975 | 0.79 | CA12 (0.50) | DNM1CES2CES1MEN1FAAH | |
| SCHEMBL25270460 | 0.79 | CA12 (0.50) | DNM1CES2CES1MEN1FAAH | |
| SCHEMBL25226892 | 0.79 | CA12 (0.50) | DNM1CES2CES1MEN1FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11926846-B2 | Hydroxyurea to enhance sperm cells | MEHARRY MEDICAL COLLEGE (US) | 2024-03-12 | — | — | US | disclosed |
| US-20200087619-A1 | HYDROXYUREA TO ENHANCE SPERM CELLS | MEHARRY MEDICAL COLLEGE | 2020-03-19 | — | — | US | disclosed |
| EP-3621603-A1 | HYDROXYUREA TO ENHANCE SPERM CELLS | Meharry Medical College (US) | 2020-03-18 | — | — | EP | disclosed |
| WO-2018208826-A1 | HYDROXYUREA TO ENHANCE SPERM CELLS | MEHARRY MEDICAL COLLEGE (US) | 2018-11-15 | — | — | WO | disclosed |
| US-20170290820-A1 | METHODS AND COMPOSITIONS FOR TREATING BETA-THALASSEMIA AND SICKLE CELL DISEASE | ACADEMIA SINICA (TW) | 2017-10-12 | — | — | US | disclosed |
| US-9662324-B2 | Methods and compositions for treating β-thalassemia and sickle cell disease | ACADEMIA SINICA (TW) | 2017-05-30 | — | — | US | disclosed |
| US-20160106728-A1 | METHODS AND COMPOSITIONS FOR TREATING BETA-THALASSEMIA AND SICKLE CELL DISEASE | ACADEMIA SINICA (TW) | 2016-04-21 | — | — | US | disclosed |
| WO-2014179567-A2 | METHODS AND COMPOSITIONS FOR TREATING BETA-THALASSEMIA AND SICKLE CELL DISEASE | ACADEMIA SINICA (TW) | 2014-11-06 | — | — | WO | disclosed |
| EP-1146904-A4 | USE OF HYDROXYUREA AND A REVERSE TRANSCRIPTASE INHIBITOR TO INDUCE AUTOVACCINATION BY AUTOLOGOUS HIV | LORI FRANCO (US) | 2004-09-15 | — | — | EP | disclosed |
| EP-1146904-A1 | USE OF HYDROXYUREA AND A REVERSE TRANSCRIPTASE INHIBITOR TO INDUCE AUTOVACCINATION BY AUTOLOGOUS HIV | Lori, Franco (US) | 2001-10-24 | — | — | EP | disclosed |
| WO-2000045844-A1 | USE OF HYDROXYUREA AND A REVERSE TRANSCRIPTASE INHIBITOR TO INDUCE AUTOVACCINATION BY AUTOLOGOUS HIV | LORI FRANCO (US) | 2000-08-10 | — | — | WO | disclosed |
| WO-1999048526-A1 | METHOD OF RENDERING A HUMAN IMMUNODEFICIENCY VIRUS POPULATION REPLICATION INCOMPETENT $i(IN VIVO) | LORI FRANCO (US) | 1999-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170290820-A1 | METHODS AND COMPOSITIONS FOR TREATING BETA-THALASSEMIA AND SICKLE CELL DISEASE | HBB, HBZ, HBG1 | KDM5A 3974/4885PHF8 3682/4885KDM4C 3572/4885 |
| US-11926846-B2 | Hydroxyurea to enhance sperm cells | NASP, ACR, CATSPER1 | KDM5A 2216/4885PHF8 142/4885KDM4C 2133/4885 |
| US-20200087619-A1 | HYDROXYUREA TO ENHANCE SPERM CELLS | NASP, ACR, CATSPER1 | KDM5A 2216/4885PHF8 142/4885KDM4C 2133/4885 |
| US-20160106728-A1 | METHODS AND COMPOSITIONS FOR TREATING BETA-THALASSEMIA AND SICKLE CELL DISEASE | HBB, HBZ, HBG1 | KDM5A 3974/4885PHF8 3682/4885KDM4C 3572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.